ArticleArteriosclerosis, thrombosis, and vascular biology2026
Antithrombotic Therapy on Antithrombin Resistance in a Mouse Model.
Article in Arteriosclerosis, thrombosis, and vascular biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAntithrombin resistance (ATR) is a congenital thrombotic predisposition caused by abnormal prothrombin, FII (Factor II). Abnormal FII with ATR characteristics, when converted to thrombin, FIIa (Factor IIa), shows a reduced affinity of binding to AT (antithrombin), resulting in reduced anti-FIIa and a thrombotic tendency. Data on the efficacy of anticoagulants in ATR are currently insufficient.
methodsMouse models of ATR were generated to investigate the efficacy of anticoagulants. Because FII R596L, which causes ATR in humans, was considered to correspond to R593L in mice based on gene sequence analysis, knock-in mice that systemically express FII R593L were generated. First, the nature of ATR was confirmed by blood coagulation analysis. We then evaluated thrombotic tendency at the individual level using an inferior vena cava stenosis model, and evaluated the antithrombotic effects of unfractionated heparin, low molecular weight heparin, synthetic pentasaccharide, and direct oral anticoagulants.
resultsIn coagulation studies, R593L Homo and Hetero mice (R593L Homo and Hetero, respectively) exhibited lower FII antigen levels and lower FIIa generation potential than wild-type mice, but residual FIIa activity after addition of AT confirmed the presence of ATR properties. In the inferior vena cava stenosis model, significantly higher thrombus formation was maintained in R593L Homo and Hetero compared with wild-type, even 96 hours after inferior vena cava stenosis. In anticoagulant administration experiments, anticoagulants with anti-FIIa effects appeared more effective against FII R593L.
conclusionsKnock-in of FII R593L produced ATR model mice, which showed a strong thrombotic tendency. Evaluation of antithrombotic therapies showed that anticoagulants with anti-FIIa effects were highly effective.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.